Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6280071 | 0.83 | NPC1 (0.59) | TP53MEN1KMT2AMAPTPOLB | |
| SCHEMBL6282492 | 0.82 | MEN1 (0.50) | ARTHRBTP53PABPC1MEN1 | |
| SCHEMBL6276823 | 0.80 | MAPT (0.55) | MEN1KMT2AMAPTPOLB | |
| SCHEMBL8360122 | 0.80 | MAPT (0.55) | MEN1KMT2AMAPTPOLB | |
| SCHEMBL6313465 | 0.80 | MAPT (0.55) | MEN1KMT2AMAPTPOLB | |
| SCHEMBL6281551 | 0.80 | PTGDR2 (0.64) | PTGDR2MAPT | |
| SCHEMBL6279563 | 0.80 | ALDH1A1 (0.51) | THRBTP53MEN1KMT2AMAPT | |
| SCHEMBL6285172 | 0.79 | ALDH1A1 (0.67) | MEN1KMT2AMAPTPOLB | |
| SCHEMBL6284250 | 0.77 | ALDH1A1 (0.55) | TP53MAPT | |
| SCHEMBL6282432 | 0.76 | L3MBTL1 (0.69) | MEN1KMT2AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY | 2003-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | CASP1, IRAK1, STS | AR 3407/4885THRB 2057/4885TP53 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.